Altor Bioscience, LLC

Culver City, CA Part of Nantcell, Inc.

UEI
MNK5L65P4L94
CAGE
46J20
Primary NAICS
325412 Pharmaceutical Preparation Manufacturing
SAM.gov registration
Active through

Company facts

Self-certified in SAM.gov
  • For Profit Organization
Entity structure
Corporate Entity (Not Tax Exempt)
Corporate family
  • Nantcell, Inc. Parent Culver City, CA XLVDBMKZ3BA6
    • Altor Bioscience, LLC
SAM.gov registration date
Physical address
9920 Jefferson Blvd, Culver City, CA 90232, USA
Website
immunitybio.com
Founded
2014
Employees
251-1K
Estimated annual revenue
$10M-$50M
Industry
  1. Health Care
  2. Pharmaceuticals, Biotechnology & Life Sciences
  3. Pharmaceuticals
SIC code
28 Chemical & Allied Products
Profiles

Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .

Contract vehicles

Grant awards

Award Agency Obligated Awarded
Combination immunotherapy of a novel superagonist IL-15 complex and anti-CD20 antibody for indolent non-hodgkin lymphoma R44CA195812 National Cancer Institute (NIH) $1,893,761
CD20-targeted IL-15 immunotherapeutic for b-cell malignancies R43CA174091 National Institutes of Health $257,303
IL-15 superagonist complex as an immunotherapeutic for multiple myeloma R43CA167925 National Institutes of Health $231,853
IL-15 superagonist complex as an immunotherapeutic for multiple myeloma R44CA167925 National Cancer Institute (NIH) $1,124,972
Novel IL-15 superagonist therapy for bladder cancer R43CA156740 National Institutes of Health $225,279

Latest 5 listed here. See the rest on GovTribe.

Quick answers

Is Altor Bioscience, LLC registered in SAM.gov?

Yes. Altor Bioscience, LLC's SAM.gov registration is active through January 27, 2027.

Which contract vehicles does Altor Bioscience, LLC hold?

Altor Bioscience, LLC holds a place on 1 federal contract vehicle: FSS-61-IB.

What is Altor Bioscience, LLC's most recent federal award?

Altor Bioscience, LLC's most recent federal grant award is Combination immunotherapy of a novel superagonist IL-15 complex and anti-CD20 antibody for indolent non-hodgkin lymphoma (R44CA195812), from National Cancer Institute (NIH), on September 30, 2015.

On GovTribe

See Altor Bioscience, LLC's full federal record

  • IDV awards
  • Contract vehicles
  • Federal grant awards
  • Funding analysis by agency, NAICS and set-aside
  • Similar vendors
Try for free Login